Molecular characteristics of early‐onset pancreatic ductal adenocarcinoma

• Published in: Molecular oncology Vol. 18; no. 3; pp. 677 - 690
• Main Authors: Debernardi, Silvana, Liszka, Lukasz, Ntala, Chara, Steiger, Katja, Esposito, Irene, Carlotti, Emanuela, Baker, Ann‐Marie, McDonald, Stuart, Graham, Trevor, Dmitrovic, Branko, Feakins, Roger M., Crnogorac‐Jurcevic, Tatjana
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01-03-2024; Wiley
• Subjects: Adenocarcinoma; Age; Bar codes; early onset pancreatic cancer; Enzymes; Genes; Genetic testing; Genomes; K-Ras protein; KRAS; Metastases; Metastasis; Molecular modelling; Mutation; p16; p53; p53 Protein; Pancreatic cancer; Quality control; SMAD4; Smad4 protein; Tumors; tumour heterogeneity; England; United Kingdom > UK; United States > US; Germany; early onset pancreatic cancer; SMAD4; KRAS; p16; p53; tumour heterogeneity
• ISSN: 1574-7891; 1878-0261
• DOI: 10.1002/1878-0261.13576

The median age of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis is 71 years; however, around 10% present with early‐onset pancreatic cancer (EOPC), i.e., before age 50. The molecular mechanisms underlying such an early onset are unknown. We assessed the role of common PDAC drivers (KRAS, TP53, CDKN2A and SMAD4) and determined their mutational status and protein expression in 90 formalin‐fixed, paraffin‐embedded tissues, including multiple primary and matched metastases, from 37 EOPC patients. KRAS was mutated in 88% of patients; p53 was altered in 94%, and p16 and SMAD4 were lost in 86% and 71% of patients, respectively. Meta‐synthesis showed a higher rate of p53 alterations in EOPC than in late‐onset PDAC (94% vs. 69%, P = 0.0009) and significantly higher loss of SMAD4 (71% vs. 44%, P = 0.0025). The majority of EOPC patients accumulated aberrations in all four drivers; in addition, high tumour heterogeneity was observed across all tissues. The cumulative effect of an exceptionally high rate of alterations in all common PDAC driver genes combined with high tumour heterogeneity suggests an important mechanism underlying the early onset of PDAC.
The molecular mechanisms underlying early‐onset pancreatic cancer (EOPC) in patients younger than 50 are unclear. Using 90 primary and matched metastases from 37 EOPC patients, we found that the majority bear alterations in all common PC drivers (KRAS, CDKN2A, TP53 and SMAD4) and show exceptionally high tumour heterogeneity in the latter three, likely contributing to such an early disease onset.